BAUDETTE, Minn., Sept. 11, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Vancomycin HCl for Oral Solution, 250mg per 5mL (the generic equivalent ...
Amneal is voluntarily recalling four lots of Vancomycin Hydrochloride for Oral Solution, 250 mg/5 mL packaged in 80 mL, 150 mL or 300 mL pack sizes, to the consumer level. Some bottles may have been ...
During the manual bottle filling stage of manufacturing, some bottles may have been overfilled resulting in an over potent dosing regimen. Amneal Pharmaceuticals, LLC is voluntarily recalling 4 lots ...
Vancomycin is indicated to treat enterocolitis caused by Staphylococcus aureus and antibiotic-associated pseudomembranous colitis caused by C. difficile. ANI Pharmaceuticals announced that the Food ...
WILMINGTON, Mass., Jan. 29, 2018 /PRNewswire/ -- CutisPharma announced today that the US Food and Drug Administration (FDA) has approved FIRVANQ™ (vancomycin hydrochloride) for oral solution, for the ...
Amneal Pharmaceuticals, LLC. Bridgewater, New Jersey (Amneal), is voluntarily recalling 4 lots (see table below) of Vancomycin Hydrochloride for Oral Solution, USP, 250 mg/5mL packaged in 80 mL, 150 ...
Azurity Pharmaceuticals, Inc. — a pioneer drug company that markets its FDA-approved oral vancomycin hydrochloride solution, FIRVANQ® — has sued Edge Pharma, LLC, an outsourcing facility operating ...
The FDA on Monday granted approval to CutisPharma’s drug Firvanq to treat Clostridium difficile-associated diarrhea and Staphylococcus aureus-associated intestinal inflammation (enterocolitis). Here ...
Please provide your email address to receive an email when new articles are posted on . Clinical response was noted in 47.6% of patients treated with oral vancomycin therapy for IBD associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback